Schering-Plough's Noxafil approved in European Union for treatment of invasive fungal infections

By Angela McDaniels

Seattle, Oct. 27 - Schering-Plough Corp. said the European Commission has granted marketing approval to Noxafil (posaconazole) oral suspension.

The approval follows a positive opinion granted on July 27 by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

This is Noxafil's first marketing approval.

Noxafil is used in treating invasive fungal infections in adult patients with refractory disease or who are intolerant of certain commonly used antifungal agents.

Schering-Plough is a pharmaceutical company based in Kenilworth, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.